It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
scientific solutions | protein science & Structural Biology
X-Ray Crystallography
At Sygnature Discovery, we help you unlock structural insights that drive drug discovery forward. Our X-ray crystallography services deliver accurate protein structures and protein-ligand complexes, supporting everything from early-stage research to fragment-based lead generation (FBLG). Every project is tailored to your goals, combining advanced technology with decades of expertise.
Crystallography is rarely a straight line, it’s an iterative process. Each stage can reveal new data that shapes the next step. For example, an expression test might uncover a degradation product, prompting us to look for a more stable, crystallizable region of the target protein.
When that happens, we confirm domain boundaries and reorder the gene to optimize results. To keep projects efficient and transparent, we break them into clear stages with Stop/Go decision points.
Protein Construct Design
We design constructs to give your protein the best chance to succeed from the start:
• Bioinformatics and modelling guide every decision
• Affinity tags simplify expression and purification while meeting end-use requirements
• Chimeras, mutations, truncations, deletions tailored to your project needs.
• IMPROvER software enhances membrane protein stability.
Crystallization
We combine precision and automation delivering an efficient process to maximize crystallization success:
Initial screening with commercial and in-house sparse matrix screens
Thermofluor screens to explore buffers, pH, additives, substrates, cofactors, ions
Co-crystallization with tool compounds when required
Fragment screening options available
Automated crystallization and imaging using:
Dragonfly for screen optimization
Mosquito ultra-low volume liquid handling to minimize protein use
Formulatrix Rock Imager 1000 plate hotel
Rockmaker data analysis
CrystalShifter for efficient crystal harvesting
X-Ray Data Collection
We generate high-quality data at leading synchrotron facilities
• Access to third-generation light sources such as Diamond, ESRF, Soleil, and SLS
• Reserved data collection slots for predictable timelines
• Flexibility beamtime for accelerated turnaround when needed
Structure Determination
Our team applies proven methods to deliver accurate informative structures:
• Molecular Replacement or de novo phasing using Se-Met or SAD/MAD
• Multiple rounds of refinement for precision and reliability
Hear From One of our Experts
Our talented crystallography team brings decades of experience in solving X-ray crystal structures over a wide range of different protein classes. Our proven expertise ranges from de-novo protein structure determination of challenging targets to delivering rapid turnaround protein-ligand complexes as well as managing X-ray based FBLG projects.
Derek Ogg
Chief Scientific Officer and Protein Crystallographer
The concept of Targeted Protein Degradation (TPD) covers all techniques that exploit the natural mechanisms of cellular degradation to target a disease-causing protein for destruction.
Case Studies
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Main home page for the Protein Science and Structural Biology Department. We take time to understand your target and the ultimate aims of the project and tailor our approach accordingly.
From high -quality starting points to optimized leads, we unite fragment screening, structural biology, computational chemistry and medicinal chemistry to keep your program moving forward .
We provide various NMR services, including protein characterization and ligand binding in solution, fragment-based drug discovery and gene to NMR structure determination.
![Sygnature TL1A [C95S/C135S] Structure](https://www.sygnaturediscovery.com/wp-content/uploads/2025/12/Sygnature-TL1A-Structure-400x359-1.webp)
